|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We engineered antibody fragments targeting human CD20 and studied their potential as immunoPET tracers in transgenic mice (huCD20TM) and in a murine lymphoma model expressing human CD20.<b>Experimental Design:</b> Anti-CD20 cys-diabody (cDb) and cys-minibody (cMb) based on rituximab and obinutuzumab (GA101) were radioiodinated and used for immunoPET imaging of a murine lymphoma model.
|
28928164 |
2017 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of patients with relapsed or refractory low grade follicular B-NHL lymphoma with rituximab (chimeric anti-CD20 mAb) has resulted in approximately 50% response rate.
|
19885551 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Measles virus (MV)-PNP H(blind)antiCD20 is a CD20-targeted and prodrug convertase-armed MV that temporarily controls growth of lymphoma xenografts in severe combined immunodeficiency (SCID) mice in combination with fludarabine phosphate (fludarabine).
|
20686506 |
2010 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The patient was tentatively diagnosed with primary cutaneous CD30-negative large T-cell lymphoma with aberrant CD20 co-expression, pending workup to exclude systemic lymphoma with cutaneous involvement.
|
25942672 |
2015 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytotoxic effects of RDMs in combination with ultrasound (RDMs+US) were evaluated in vitro in CD20+ and CD20- cell lines, and its antitumor activities were assessed in Raji (CD20+) and Jurkat (CD20-) lymphoma cell-grafted mice.
|
27902473 |
2017 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
|
24358223 |
2013 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have identified a spliced mRNA transcript of CD20 (named D393-CD20) which was associated with resistance to RTX in primary B cell from patients with lymphoma and leukaemia.
|
24313590 |
2014 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach.
|
17438098 |
2007 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetically induced lymphoma Gal-1 expression ablated antibody-dependent lymphoma phagocytosis in vitro and lymphoma sensitivity to CD20 immunotherapy in vivo.
|
26888257 |
2016 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, in contrast to parental NK-92, CD20-specific NK cells efficiently lysed CD20 expressing but otherwise NK-resistant established and primary lymphoma and leukemia cells, demonstrating that this strategy can overcome NK-cell resistance and might be suitable for the development of effective cell-based therapeutics for the treatment of B-cell malignancies.
|
17717662 |
2008 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD20 monoclonal antibody (mAb) rituximab has been used successfully for lymphoma therapy for more than 10 years.
|
20439625 |
2010 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study showed that lymphoma xenografts could be targeted in the presence of endogenous biotin when anti-CD20 fusion proteins containing SAv mutants (scFv(4)-SAv-S45A or scFv(4)-SAv-Y43A) were employed in combination with CA 2 and [(111)In]4b.
|
20597486 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both patients were diagnosed with NMOSD and initiated on anti-CD20 agents prior to lymphoma diagnosis, though the short duration of exposure argues against a direct role.
|
31706113 |
2020 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fusion proteins had reduced IFNalpha activity in vitro compared with native IFNalpha, but CD20 targeting permitted efficient antiproliferative and proapoptotic effects against an aggressive rituximab-insensitive human CD20(+) murine lymphoma (38C13-huCD20) and a human B-cell lymphoma (Daudi).
|
20139095 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We and others have previously reported that immunoglobulin G Fc receptor (FcgammaR) polymorphisms predict the clinical response of lymphoma patients to passive anti-CD20 antibody infusions.
|
15483014 |
2004 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recombinant antibodies were detected in the milk of transgenic mice with the highest expression level up to 17 microg/mul and could specifically bind the CD20 surface antigens on human B-lymphoma cells.
|
18183493 |
2008 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
|
29595951 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have set up a new in vivo model in nonimmunodeficient mice by stable transduction of the human CD20 cDNA in the murine lymphoma line EL4.Animals injected i.v. with the EL4-CD20(+) lymphoma cells died within 30 days with evident liver, spleen, and bone marrow involvement, confirmed by immunohistochemistry and PCR analysis.
|
12874252 |
2003 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This is the first identified case of loss of CD20 expression in a lymphoma that has relapsed after rituximab therapy, although several other cases have since been identified.
|
10100713 |
1999 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab (RTX), for which CD20 molecule is the target, proved to be less efficient in CLL than in lymphoma.
|
19758221 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
|
22308288 |
2012 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additional immunostaining, which demonstrated positivity for CD20 and kappa light chain, as well as detection of the monoclonal rearrangement of the immunoglobulin heavy chain gene, helped to establish the diagnosis of lymphoma and to rule out an initially favored diagnosis of poorly differentiated carcinoma.
|
11473470 |
2001 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.
|
25773122 |
2015 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The therapeutic mAb rituximab induced the expression of the CCL3 and CCL4 chemokines in the human lymphoma line BJAB following binding to the CD20 Ag.
|
17475893 |
2007 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD20 monoclonal antibody rituximab has been less successful in treating chronic lymphocytic leukemia (CLL) than lymphoma, possibly due to the lower density of CD20 on B lymphocytes from CLL patients than on those from lymphoma patients.
|
18794139 |
2008 |